AVANDAMET
LOE Approachingmetformin hydrochloride; rosiglitazone maleate
NDAORALTABLET
Approved
Oct 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
4/8 — Partial
AVANDAMET (metformin hydrochloride; rosiglitazone maleate) is avandamet: avandamet combines 2 antidiabetic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: rosiglitazone, a member of the thiazolidinedione class, and metformin, a member of the biguanide class. Approved for type 2 diabetes mellitus, not already taking rosiglitazone, unable to achieve glycemic control on other diabetes medications and and 4 more indications. First approved in 2002.
Drug data last refreshed 1h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVANDAMET is a fixed-dose combination oral tablet combining rosiglitazone (a PPARγ agonist) and metformin (a biguanide) for type 2 diabetes management. It improves glycemic control through dual mechanisms: rosiglitazone enhances insulin sensitivity in adipose tissue, muscle, and liver, while metformin decreases hepatic glucose production and increases peripheral glucose uptake. The combination targets insulin resistance without inducing hypoglycemia or hyperinsulinemia.
LOE Approaching
As LOE approaches, the brand team is likely downsizing or consolidating; career growth opportunities are limited to transition planning and managed decline roles.
Mechanism of Action
AVANDAMET: AVANDAMET combines 2 antidiabetic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: Rosiglitazone, a member of the thiazolidinedione class, and metformin, a member of the biguanide class. Thiazolidinediones are insulin sensitizing…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.